Leukemia
Patients with certain blood cancers may be at risk for breakthrough COVID-19 infections
Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.
One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells
CRISPR may be the most notable name in the world of gene editing, but it’s not the only option.
Zanubrutinib extends PFS in treatment-naive CLL
Zanubrutinib prolonged PFS compared with bendamustine plus rituximab among patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma who did not harbor deletion 17p.
Ivosidenib regimen extends EFS in IDH1-mutated AML
The addition of ivosidenib tablets to azacitidine prolonged EFS among patients with previously untreated IDH1-mutated acute myeloid leukemia, according to topline data released by the agent’s manufacturer.
FDA grants fast track designation to eryaspase for hypersensitive ALL
The FDA granted fast track designation to eryaspase for treatment of patients with acute lymphoblastic leukemia who developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.
Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia
Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.
Immunization in cancer survivors: Optimizing response, minimizing risk
The COVID-19 pandemic has underscored the importance of vaccination, both in terms of protecting individuals from infection and eradicating threats to public health.
New CAR T-cell therapy uses shorter linker, leading to more potent therapy for ALL
CD19-directed chimeric antigen receptor T-cell therapies have produced unprecedented response rates among patients with advanced hematologic malignancies, yet many patients who respond to this therapy experience disease relapse.
ASH to present honorific awards
ASH will present honorific awards to several hematologists during this year’s ASH Annual Meeting, scheduled for Dec. 11-14.
Children’s Hospital of Philadelphia appoints leukemia specialist as section chief
Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.